155 related articles for article (PubMed ID: 34629213)
1. The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy.
Whisenant MS; Srour SA; Williams LA; Subbiah I; Griffin D; Ponce D; Kebriaei P; Neelapu SS; Shpall E; Ahmed S; Wang XS
Semin Oncol Nurs; 2021 Dec; 37(6):151216. PubMed ID: 34629213
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
3. The Patient Symptom Experience After Tisagenlecleucel and Lisocabtagene Maraleucel CAR T-Cell Therapy for Lymphoma.
Andersen L; Baker KM; Difilippo H; Meghani SH; Porter D; Deng J
Semin Oncol Nurs; 2024 Apr; 40(2):151614. PubMed ID: 38443220
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.
Wang XS; Srour SA; Mendoza T; Whisenant M; Subbiah I; Gonzalez E; Kamal M; Shen SE; Cleeland C; Kebriaei P; Rezvani K; Neelapu S; Ahmed S; Shpall E
Br J Haematol; 2023 May; 201(4):738-746. PubMed ID: 36733986
[TBL] [Abstract][Full Text] [Related]
5. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer.
Whisenant MS; Williams LA; Garcia Gonzalez A; Mendoza T; Shi Q; Cleeland C; Zhang J; Heymach J; Simon G
JCO Oncol Pract; 2020 Oct; 16(10):e1151-e1160. PubMed ID: 32539654
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
Chakraborty R; Sidana S; Shah GL; Scordo M; Hamilton BK; Majhail NS
Biol Blood Marrow Transplant; 2019 May; 25(5):e155-e162. PubMed ID: 30500439
[TBL] [Abstract][Full Text] [Related]
7. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
8. Telephone interventions for symptom management in adults with cancer.
Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
[TBL] [Abstract][Full Text] [Related]
9. [Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Moreau AS; Ahmad I; Borel C; Hadhoum N; Masouridi-Levrat S; Naudin J; Nicolas-Virelizier E; Ouachée-Chardin M; Platon L; Quessar A; Roth-Guepin G; Beauvais D; Baruchel A; Cornillon J
Bull Cancer; 2019 Jan; 106(1S):S102-S109. PubMed ID: 30661749
[TBL] [Abstract][Full Text] [Related]
10. Utilization of CAR T Cell Therapy in Pediatric Patients.
Szenes V; Curran KJ
Semin Oncol Nurs; 2019 Oct; 35(5):150929. PubMed ID: 31526551
[TBL] [Abstract][Full Text] [Related]
11. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
12. Advanced Practice Nursing and CAR-T Cell Therapy: Opportunities, Challenges and Future Directions.
Kisielewski D; Naegele M
Semin Oncol Nurs; 2024 Jun; 40(3):151628. PubMed ID: 38594105
[TBL] [Abstract][Full Text] [Related]
13. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
Shalabi H; Wolters PL; Martin S; Toledo-Tamula MA; Roderick MC; Struemph K; Kane E; Yates B; Delbrook C; Mackall CL; Lee DW; Fry TJ; Shah NN
J Immunother; 2018 Sep; 41(7):350-358. PubMed ID: 30048343
[TBL] [Abstract][Full Text] [Related]
14. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T.
Akinola IM; Cusatis R; Pasquini MC; Shaw BE; Bollu V; Dalal A; Tesfaye M; Flynn KE
Transplant Cell Ther; 2023 Apr; 29(4):254.e1-254.e9. PubMed ID: 36634738
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
[TBL] [Abstract][Full Text] [Related]
16. Burden of living with multiple concurrent symptoms in patients with end-stage renal disease.
Ng MSN; Wong CL; Ho EHS; Hui YH; Miaskowski C; So WKW
J Clin Nurs; 2020 Jul; 29(13-14):2589-2601. PubMed ID: 32279368
[TBL] [Abstract][Full Text] [Related]
17. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
18. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
19. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ
J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905
[TBL] [Abstract][Full Text] [Related]
20. What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer.
Whisenant MS; Strunk FA; Tripathy D; Williams LA
Support Care Cancer; 2019 Dec; 27(12):4639-4647. PubMed ID: 30937601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]